• Xyall

  Participated · Equity · Feb 2026

  Xyall BV is a molecular pathology technology company focused on automating the labor-intensive step of tissue dissection prior to PCR and next-generation sequencing analyses. Its flagship product, the Tissector TableTop, integrates high-resolution slide imaging, precise image registration, workflow software, and robotics to deliver fully automated, contamination-free tissue selection. Introduced in 2023, the system is already installed in more than 15 Tier-1 commercial, academic, pharmaceutical, and research labs, including sites in the United States. Customers adopt the platform to cope with staffing shortages and the demand for faster, more precise oncology diagnostics. By bridging morphological assessment and molecular diagnostics, Xyall positions itself as a critical enabler of personalized medicine. The company plans to use new capital to accelerate its global rollout and deepen penetration of both research and clinical laboratories. Its recent €7.6 million raise strengthens its balance sheet for these expansion efforts.

No current team members are available.